TY - JOUR T1 - Activation of CYP2C9-Mediated Metabolism by a Series of Dapsone Analogs: Kinetics and Structural Requirements JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 1194 LP - 1200 DO - 10.1124/dmd.30.11.1194 VL - 30 IS - 11 AU - J. Matthew Hutzler AU - Dhanashri Kolwankar AU - Matthew A. Hummel AU - Timothy S. Tracy Y1 - 2002/11/01 UR - http://dmd.aspetjournals.org/content/30/11/1194.abstract N2 - Cytochrome P450 2C9-mediated metabolism has been shown to be activated in the presence of the effector dapsone. However, it has yet to be established what effector structural features are necessary to activate CYP2C9 activity. To address this question, kinetic studies were conducted with nine analogs of dapsone containing various functional properties (three sulfone compounds, three carbonyl compounds, and three sulfonamide compounds), to examine the functional groups important for enzyme activation by the effector (dapsone). Results show that phenylsulfone (dapsone without thepara-amino groups) activates flurbiprofen 4′-hydroxylation comparable to dapsone but inhibits naproxen demethylation. Meanwhile, p-tolylsulfone had little effect on flurbiprofen metabolism, but activated naproxen demethylation, albeit only at high concentrations. These substrate-dependent differences in effect suggest that naproxen has a different binding orientation compared with flurbiprofen. Perhaps most interesting is that replacement of only one amino group from dapsone with a nitro group (4-(4-nitrophenylsulfonyl)-aniline) resulted in substantial inhibition of flurbiprofen 4′-hydroxylation, suggesting that electronic effects may influence activation of this substrate. Other analogs either had minor or no effect on CYP2C9-mediated metabolism. Overall, it is apparent from these studies that a sulfone group in direct association with two benzene rings withpara-electron-donating groups represents the most efficient activator of CYP2C9. However, the effects of these analogs appear to be concentration- and substrate-dependent, further complicating the prediction of these types of in vitro interactions. The American Society for Pharmacology and Experimental Therapeutics ER -